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Aims: To confirm, in a 26-week extension study, the sustained efficacy and safety of a fixed combination of insulin degludec and liraglutide (IDegLira)
compared with either insulin degludec or liraglutide alone, in patients with type 2 diabetes.
Methods: Insulin-naïve adults with type 2 diabetes randomized to once-daily IDegLira, insulin degludec or liraglutide, in addition to met-
formin± pioglitazone, continued their allocated treatment in this preplanned 26-week extension of the DUAL I trial.
Results: A total of 78.8% of patients (1311/1663) continued into the extension phase. The mean glycated haemoglobin (HbA1c) concentration at
52 weeks was reduced from baseline by 1.84% (20.2 mmol/mol) for the IDegLira group, 1.40% (15.3 mmol/mol) for the insulin degludec group and
1.21% (13.2 mmol/mol) for the liraglutide group. Of the patients on IDegLira, 78% achieved an HbA1c of <7% (53 mmol/mol) versus 63% of the patients
on insulin degludec and 57% of those on liraglutide. The mean fasting plasma glucose concentration at the end of the trial was similar for IDegLira
(5.7 mmol/l) and insulin degludec (6.0 mmol/l), but higher for liraglutide (7.3 mmol/l). At 52 weeks, the daily insulin dose was 37% lower with IDegLira (39
units) than with insulin degludec (62 units). IDegLira was associated with a significantly greater decrease in body weight (estimated treatment difference,
−2.80 kg, p< 0.0001) and a 37% lower rate of hypoglycaemia compared with insulin degludec. Overall, all treatments were well tolerated and no new
adverse events or tolerability issues were observed for IDegLira.
Conclusions: These 12-month data, derived from a 26-week extension of the DUAL I trial, confirm the initial 26-week main phase results and the
sustainability of the benefits of IDegLira compared with its components in glycaemic efficacy, safety and tolerability.
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Introduction
Basal insulin and glucagon-like peptide-1 receptor agonists
(GLP-1RAs) have complementary modes of action, and combi-
nation treatment has generated considerable interest as a treat-
ment option for patients with type 2 diabetes (T2D). GLP-1RAs
reduce food intake and promote weight loss [1] and have the
additional benefit of a low risk of hypoglycaemia compared
with basal insulin [2,3]. These features may be helpful in over-
coming some aspects of clinical inertia with respect to inten-
sifying therapy in patients with T2D [4]. A fixed-ratio soluble
combination of insulin degludec and liraglutide [IDegLira; 100
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units and 3.6 mg/ml, respectively (Xultophy®)] was approved
in 2014 by the European Medicines Agency and is delivered via
pen-device. This combination allows both active ingredients to
be administered with a single injection.
Results from the previously published, 26-week randomized,
controlled trial (DUAL I) showed that treatment with IDegLira
resulted in a substantial improvement in glycaemic control, in
conjunction with a lower risk of hypoglycaemia and weight loss
compared with insulin degludec alone, and with better glucose
control and fewer gastrointestinal (GI) side effects compared
with liraglutide alone [5]. The objectives of the present exten-
sion study were to assess the sustainability of the treatment
response of IDegLira over 52 weeks and to obtain additional
data regarding safety. Data were also analysed post hoc to evalu-
ate whether the effects of IDegLira were applicable to different
body mass index (BMI) categories, given that obesity is one of
the most common comorbidities for patients with T2D.
The trial was registered at ClinicalTrials.gov under the num-
ber: NCT01336023.
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Methods
We describe the 26-week extension of DUAL I, a phase III, ran-
domized, open-label, three-arm, parallel-group, 26-week trial
in insulin-naïve adults (≥18 years) with T2D conducted at 271
sites (19 countries). The original study has been described pre-
viously [5] and further detail on study methods is also pro-
vided in Table S1 of File S1. Briefly, patients were randomized
(2 : 1 : 1) to once-daily injections of IDegLira, insulin degludec
or liraglutide (open-label), with patients stratified for the fol-
lowing factors: baseline glycated haemoglobin (HbA1c) con-
centration [HbA1c ≤8.3 or >8.3% (≤67 or >67 mmol/mol)];
concomitant oral antidiabetic drug (OAD) treatment (met-
formin background or metformin+ pioglitazone background);
and participation in a substudy involving a standardized meal
test and continuous glucose monitoring [6,7].
IDegLira (insulin degludec 100 U/ml plus liraglutide
3.6 mg/ml), insulin degludec (100 U/ml) and/or liraglutide
(6 mg/ml) were all administered subcutaneously. The IDegLira
dosing unit is defined as a dose step, with one dose step com-
prising 1 unit of insulin degludec and 0.036 mg liraglutide in a
volume of 0.01 ml. IDegLira was started at 10 dose steps (10 U
insulin degludec plus 0.36 mg liraglutide, once daily).
As in the original 26-week trial, adjustment of IDegLira was
performed twice weekly based on the mean of three consecu-
tive daily fasting self-monitored blood glucose (SMBG) mea-
surements immediately before dose adjustment. Adjustments
occurred in two dose steps (2 U insulin degludec and 0.072 mg
liraglutide) to the fasting glycaemic target of 4.0–5.0 mmol/l
(72–90 mg/dl). Insulin degludec treatment was initiated with
10 U, and titrated twice weekly to the fasting glycaemic tar-
get of 4.0–5.0 mmol/l (72–90 mg/dl) based on the mean SMBG
(fasting) from three preceding measurements as described for
IDegLira. IDegLira, at the maximum allowable dose of 50
dose steps, provides 50 units of insulin degludec and 1.8 mg
of liraglutide. There was no limit to the titration of insulin
degludec. Liraglutide treatment was started at 0.6 mg/day and
subsequently increased by 0.6 mg in weekly dose escalation
steps to a maximum dose of 1.8 mg/day. Liraglutide dose was
to remain unchanged after dose escalation to 1.8 mg/day. In the
extension phase, the twice-weekly adjustment of IDegLira and
insulin degludec, aiming at the same fasting glucose target, was
to be continued.
The primary endpoint of DUAL 1 was change from base-
line in HbA1c at 26 weeks of treatment. The 52-week secondary
endpoints included change from baseline in HbA1c concen-
tration, percentage of patients reaching HbA1c targets of <7
and ≤6.5%, and changes from baseline in laboratory-measured
fasting plasma glucose (FPG), body weight, insulin dose and
nine-point SMBG profiles. Post hoc analyses were performed
to examine whether the effects of IDegLira (regarding HbA1c,
insulin dose and hypoglycaemia) were consistent across the
range of baseline BMI categories.
Protocol-defined safety variables are presented in Table S1 of
File S1. With respect to relationship to trial product, ‘probably’
related adverse events (AEs) were those with good reason
and sufficient documentation to assume a causal relationship,
‘possibly’ related AEs were those for which a causal relationship
was conceivable and could not be dismissed. AEs determined
to be ‘unlikely’ to be related to trial products were those that
did not fit into either one of the above categories. Certain types
of AEs (pancreatitis or suspicion of pancreatitis, neoplasms,
thyroid disease requiring thyroidectomy and cardiovascular
disease) were adjudicated by an independent external adju-
dication committee (EAC) that was blinded to treatment
assignment (Table S2, File S1). The EAC was divided into three
subcommittees that evaluated events according to areas of
expertise: cardiovascular events (two cardiologists and two
neurologists); pancreatitis events (two gastroenterologists);
neoplasms; and thyroid disease requiring thyroidectomy (two
oncologists and one endocrinologist). Diagnostic criteria for
the individual adjudicated AEs were established via a specific
EAC Charter before the trial initiation. Positively adjudicated
events were those AEs which the EAC confirmed met these
predefined criteria. Calcitonin monitoring was included in
the trial, supervised by an independent calcitonin monitoring
committee of thyroid experts.
Statistical Analysis
An analysis of covariance (ancova) model was used for efficacy
analysis (HbA1c) on the full analysis set, with treatment, pre-
vious OADs, baseline HbA1c stratum, substudy participation
and country as fixed factors, and the corresponding baseline
value as covariate. The last observation carried forward (LOCF)
approach was used to impute missing values for endpoints
derived at 52 weeks of treatment. Changes from baseline after
52 weeks of treatment in body weight, laboratory-measured
FPG, and endpoints derived from nine-point SMBG profiles
were analysed separately using a similar ancova model to that
used for the primary endpoint; however, for end-of-trial dose,
baseline HbA1c was included as a covariate instead of base-
line dose. The number of confirmed hypoglycaemic episodes
was analysed using a negative binomial regression model with
a log-link function and treatment, previous OADs, baseline
HbA1c stratum, substudy participation and country as fixed
factors, and the logarithm of the exposure time as offset [8]. As
post hoc analyses, change in HbA1c from baseline, end-of-trial
insulin dose and the number of confirmed hypoglycaemic
episodes were analysed for the following baseline BMI cat-
egories: <25; ≥25 to <30; ≥30 to <35; and ≥35 kg/m2. All
post hoc endpoints were analysed using the prespecified mod-
els as described above. Additional information about statistical
methods is available in the publication of the 26-week main
trial [5] and in Table S1 of File S1.
Results
The baseline characteristics of the patients included in the
study are shown in Table 1 and Figure S1 of File S1 shows the
patient disposition. Treatment groups remained well matched,
and similar proportions of patients randomized in the main
trial continued into the extension phase (79.7, 80.4 and 75.4%
for IDegLira, insulin degludec and liraglutide, respectively).
The lower proportion for the liraglutide arm reflects the higher
discontinuation rate at the initiation of treatment, mainly as a
result of GI side effects.
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Age, years 55.1 (9.9) 54.9 (9.7) 55.0 (10.2)
Weight, kg 87.2 (19.0) 87.4 (19.2) 87.4 (18.0)
Body mass index, kg/m2 31.2 (5.2) 31.2 (5.3) 31.3 (4.8)
Duration of diabetes,
years
6.6 (5.1) 7.0 (5.3) 7.2 (6.1)
HbA1c, % 8.3 (0.9) 8.3 (1.0) 8.3 (0.9)
HbA1c, mmol/mol 67 (9.7) 67 (10.7) 67 (10.3)
Fasting plasma glucose,
mmol/l
9.2 (2.4) 9.4 (2.7) 9.0 (2.6)
OAD at screening, n (%)
Metformin 691 (83.0) 343 (83.1) 338 (81.6)
Metformin+
pioglitazone†
142 (17.0) 70 (16.9) 75 (18.1)
Data are mean (standard deviation) unless otherwise stated. IDegLira, insulin
degludec/liraglutide combination; OAD, oral antidiabetic drug.
*Full analysis set.
†One patient in the liraglutide group was receiving metformin+ glimepiride at
screening; the median daily dose of metformin at screening was 2000 mg; the median
daily dose of pioglitazone at screening was 30 mg.
At 52 weeks, the mean HbA1c concentration was reduced
to a significantly greater extent with IDegLira compared
with insulin degludec alone [−1.84 vs −1.40% (−20.2 vs
−15.3 mmol/mol); estimated treatment difference (ETD)
−0.46%, 95% confidence interval (CI) −0.57, −0.34
(−5.0 mmol/mol, 95% CI −6.3, −3.7); p< 0.0001] and
compared with liraglutide alone [−1.84 vs −1.21% (20.2
vs 13.2 mmol/mol); ETD −0.65%, 95% CI −0.76, −0.53
(−7.1 mmol/mol, 95% CI −8.3, −5.8); p< 0.0001 (Figure 1A)],
mirroring the main trial results after 26 weeks. The sensitivity
analyses on the per protocol set, the completer analysis set and
the mixed model for repeated measurement analysis confirmed
these results (Table S3, File S1). After 52 weeks, a significantly
greater proportion of patients using IDegLira (78.2 vs 66.9%)
reached HbA1c targets of either <7.0% (53 mmol/mol) or
≤6.5% (48 mmol/mol), respectively, compared with either
insulin degludec (62.5 vs 49.2%) or liraglutide [56.5 vs 38.2%:
all comparisons vs IDegLira; p< 0.0001 (Figure 2A)]. The
percentage of responders without weight gain and without
confirmed hypoglycaemia is shown in Table S4 of File S1. In
the post hoc analysis, the decrease in HbA1c concentration
was significantly greater for IDegLira than for either insulin
degludec or liraglutide across all baseline BMI categories [all
comparisons p< 0.001 (Figure 2B)].
At 52 weeks, mean [± standard deviation (s.d.)] FPG was 5.7
(±2.0) mmol/l for IDegLira, compared with 6.0 (±2.5) mmol/l
for insulin degludec and 7.3 (±2.5) mmol/l for liraglutide.
The decrease in FPG from baseline at 52 weeks was similar
for IDegLira versus insulin degludec (ETD −0.20 mmol/l,
95% CI −0.45, 0.05; p= 0.11). The reduction in mean FPG was
twofold greater for IDegLira compared with liraglutide [change
from baseline −3.45 mmol/l compared with −1.67 mmol/l for
IDegLira and liraglutide, respectively; ETD −1.67 mmol/l,
95% CI −1.92, −1.42; p< 0.0001 (Figure 3)]. The overall
mean nine-point SMBG profiles decreased across all treat-
ment groups by 52 weeks (Figure S2, top, File S1). The overall
mean nine-point SMBG for IDegLira was significantly lower
compared with insulin degludec (ETD −0.30 mmol/l, 95% CI
−0.50, −0.11; p= 0.0025) and liraglutide (ETD −0.99 mmol/l,
95% CI −1.19, −0.80; p< 0.0001). The postprandial glucose
increment was significantly lower for IDegLira than for insulin
degludec after all main meals (Figure S2, bottom, File S1).
Mean daily doses of the insulin degludec and liraglutide
components were significantly lower with combination therapy
than with either product used alone (Figure 1B). At 52 weeks,
the mean (± s.d.) daily insulin dose was 39 (± 13) units
and 62 (± 42) units for patients treated with IDegLira and
insulin degludec, respectively (ETD −23.4 units, 95% CI −26.4,
−20.3; p< 0.0001). The lower insulin dose in patients treated
with IDegLira compared with insulin degludec was significant
regardless of baseline BMI category (all p< 0.0001). During
the 26-week extension, the mean daily insulin dose contin-
ued to increase for insulin degludec, with only a one-dose step
increase for IDegLira. The mean liraglutide dose was lower for
the IDegLira group than for the liraglutide group throughout
the trial and at week 52 (1.4± 0.5 vs 1.8± 0.7 mg, respectively).
At the completion of the extension period, a higher percentage
of patients, 351/621 (56.5%), had reached the maximum dose
of IDegLira (50 dose steps) compared with the initial 26 weeks
(end of main phase of the trial): 324/734 (44.1%). The mean (±
s.d.) HbA1c values for IDegLira were 6.6± 1.1 and 6.5± 1.0%,
at 52 and 26 weeks, respectively The proportion of patients on
maximum dose of IDegLira reaching the American Diabetes
Association (ADA) target of HbA1c <7.0% was 70.1% at the
end of the extension trial, which was similar to that at 26 weeks
(73.8%).
With IDegLira, body weight remained relatively stable
throughout the trial, whereas it increased with insulin
degludec both in the original 26-week main phase as well
as during the 26-week extension; the weight decrease with
liraglutide occurred primarily during the original 26 weeks,
but was sustained throughout the 26-week extension period
(Figure 1C). At 52 weeks of treatment, change in body weight
from baseline was −0.4, +2.3 and −3.0 kg with IDegLira,
insulin degludec and liraglutide, respectively, and the treat-
ment differences were statistically significant for IDegLira
versus both insulin degludec and liraglutide (Figure 1C). As
shown in Table S4 of File S1, more patients randomized to
IDegLira achieved either ADA (HbA1c< 7.0%) or American
Association of Clinical Endocrinologists (AACE)/International
Diabetes Federation (IDF) targets (HbA1c≤ 6.5%) without
weight gain and/or without confirmed hypoglycaemia than
patients randomized to insulin degludec (all comparisons
p< 0.0001). The largest proportion of patients achieving the
ADA target without weight gain and without confirmed hypo-
glycaemia was in the group allocated to liraglutide (p= 0.0007).
These findings were generally similar to those reported at 26
weeks [5].
The rates of confirmed hypoglycaemic events per 100
patient-years of exposure (PYE) were 176.7, 279.1 and 19.1 for
IDegLira, insulin degludec and liraglutide, respectively. The
Volume 17 No. 10 October 2015 doi:10.1111/dom.12498 967
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Figure 1. (A) Mean glycated haemoglobin (HbA1c) concentration over time, by treatment group. Mean values with error bars [standard error of the mean
(s.e.m.)] based on the full analysis set (FAS) and LOCF-imputed data. p values from an analysis of covariance (ANCOVA) model. Dashed lines (--): American
Diabetes Association HbA1c target <7.0%; International Diabetes Federation HbA1c target ≤6.5%. (B) Mean daily doses of insulin degludec and liraglutide
components of treatment, over time. Mean values with error bars (s.e.m.) based on safety analysis set and LOCF-imputed data; n for each treatment based
on FAS; week 52 dose is observed dose based on FAS. (C) Change in mean body weight over time, by treatment group. Mean values with error bars (s.e.m.)
based on FAS and LOCF-imputed data. Estimated treatment differences and p values are from an ANCOVA model. EOT, end of trial; IDeg, insulin degludec;
IDegLira, insulin degludec/liraglutide combination; Lira, liraglutide. Results at 26 weeks are from the main phase of the DUAL I trial and have been reported
previously [5]).
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Figure 2. (A) Percentage of subjects reaching a glycated haemoglobin (HbA1c) target of<7.0 or≤6.5% at 26 and 52 weeks, by treatment group. Values based
on full analysis set (FAS) and LOCF-imputed data; p values are from a logistic regression model. HbA1c target <7.0% (53 mmol/mol) is from American
Diabetes Association and HbA1c target≤6.5% (48 mmol/mol) is from the International Diabetes Federation. (B) HbA1c reduction at 52 weeks by treatment
group, stratified by baseline BMI. Data are mean from observed values based on FAS and LOCF-imputed data; p values from ANCOVA model. n, number of
subjects contributing to the analysis. IDeg, insulin degludec; IDegLira, insulin degludec/liraglutide combination; Lira, liraglutide. Results at 26 weeks are
from the main phase of the DUAL I trial and have been reported previously [5].
rate of confirmed hypoglycaemia after 52 weeks of treatment
was significantly lower for IDegLira versus insulin degludec
[rate ratio 0.63 (95% CI 0.50, 0.79); p< 0.0001] and signifi-
cantly greater for IDegLira versus liraglutide [rate ratio 8.52
(95% CI 6.09, 11.93); p< 0.0001] (Figure S3, top, File S1). The
rates of confirmed nocturnal hypoglycaemic events were 22.3,
36.6 and 1.8 per 100 PYE, for IDegLira, insulin degludec and
liraglutide, respectively. There was a significant difference in
the number of confirmed nocturnal hypoglycaemic episodes
between IDegLira and liraglutide [rate ratio 11.99 (95% CI
4.85, 29.63); p< 0.0001] with fewer in the liraglutide group,
but there was no significant difference between IDegLira and
insulin degludec [rate ratio 0.68 (95% CI 0.44, 1.06); p= 0.09
(Figure S3, bottom, File S1)]. There were three confirmed
severe events with IDegLira, two with insulin degludec and
two with liraglutide. When stratified by baseline BMI, the
Volume 17 No. 10 October 2015 doi:10.1111/dom.12498 969
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Figure 3. Fasting plasma glucose (FPG) from 0 to 52 weeks by treatment group. Mean values with error bars (standard error of the mean) based on
full analysis set and LOCF-imputed data; p value is from an analysis of covariance model. IDeg, insulin degludec; IDegLira, insulin degludec/liraglutide
combination; Lira, liraglutide. Results at 26 weeks are from the main phase of the DUAL I trial and have been reported previously [5].
Table 2. Summary of adverse events.
IDegLira, n= 825* Insulin degludec, n= 412* Liraglutide, n= 412*
Category Week 26 Week 52 Week 26 Week 52 Week 26 Week 52
Percentage of patients with AEs† 63.2 71.2 60.2 70.6 72.6 77.2
AE rate per patient-year of exposure 4.8 4.1 4.3 3.8 6.4 5.1
Percentage of subjects with serious AEs† 2.3 4.6 1.9 5.3 3.4 5.8
Serious AE rate per PYE 0.05 0.07 0.07 0.09 0.09 0.09
AE, adverse event; IDegLira, insulin degludec/liraglutide combination; PYE, patient-year of exposure.
*Safety analysis set.
†Percentage of patients with ≥1 event. Results at 26 weeks are from the main phase of the DUAL I trial and have been reported previously [5].
rate of confirmed hypoglycaemia per 100 PYE versus insulin
degludec was numerically lower for all categories of base-
line BMI, with the rate ratio being statistically significant for
BMI≥30 to<35 kg/m2 (p= 0.0116) and for BMI≥35 kg/m2
(p= 0.0105). The rate of confirmed hypoglycaemic episodes
was significantly greater for IDegLira versus liraglutide at all
levels of baseline BMI [p< 0.0001 (Figure S4, File S1)].
Similar to the first 26 weeks, the most frequently reported
AEs were headache, nausea, diarrhoea, vomiting, nasopharyn-
gitis and upper respiratory tract infection. The majority of AEs
in all groups were mild in severity and judged to be unlikely
to be related to trial products by the investigator (Table 2).
The overall rate of AEs was similar with IDegLira and insulin
degludec and lower than with liraglutide (407.9 vs 383.3 vs
507.3 events per 100 PYE, respectively). During the 52-week
treatment period, the proportion of patients with AEs lead-
ing to withdrawal was lower with IDegLira (n= 14, 1.7%) and
insulin degludec (n= 9, 2.2%) than with liraglutide (n= 26,
6.3%). This appeared to be attributable to AEs occurring dur-
ing the early weeks of the main trial. When only the 26-week
extension phase was considered, withdrawals because of AEs
were fewer, and there were similar rates for all three treatment
groups (n= 5, 0.6%; n= 1, 0.2%; and n= 2, 0.5% for IDegLira,
insulin degludec and liraglutide, respectively). The increased
numbers of AEs possibly or probably related to treatment and
withdrawals attributable to AEs in the liraglutide group were
related to the higher frequency of GI events shortly after ini-
tiating liraglutide. The incidence of nausea was similar in all
three treatment groups during the extension phase (Figure S5,
File S1).
There were 109 serious AEs (SAEs) reported in 5.1% of the
patients (n= 84) over 52 weeks. The overall rate of SAEs was
6.7 per 100 PYE with IDegLira, 8.9 per 100 PYE with insulin
degludec and 9.3 per 100 PYE with liraglutide. The majority
of SAEs were unlikely to be related to trial product, but 10
SAEs reported in 9 patients (four SAEs with IDegLira, one
with insulin degludec and five with liraglutide) were possibly
or probably related to trial product.
The definition of a treatment-emergent AE has been
described previously [5]. There were five AEs reported as
pancreatitis by the investigators (three treatment-emergent
AEs: two with IDegLira and one with liraglutide; two
non-treatment-emergent AEs: one with insulin degludec
and one with liraglutide), all of which were adjudicated by
the blinded EAC. Of these, one treatment-emergent AE
(reported as acute pancreatitis in connection to a metastatic
pancreatic adenocarcinoma), was positively adjudicated in
the liraglutide group, and one non-treatment emergent AE
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was positively adjudicated in a patient who had been in the
insulin degludec group. Additionally, 16 AEs of increased
lipase and/or amylase (one screening event during the main
trial and 15 treatment-emergent AEs: 7 with IDegLira, 2 with
insulin degludec and 6 with liraglutide) were identified using
predefined searches of the safety database and assessed by
the EAC. Of these, one treatment-emergent AE (reported
as increased lipase) was adjudicated as pancreatitis in the
liraglutide group. All of the positively adjudicated events were
considered unlikely to be related to the trial drug by the local
investigator. The EAC did not assess causality with respect to
trial product for the adjudicated events.
A total of 38 treatment-emergent cardiovascular events in
24 patients were assessed by the EAC. Of these, 20 events in 13
patients were positively adjudicated (eight with IDegLira, eight
with insulin degludec and four with liraglutide), six of which
were classified as major adverse cardiovascular events (MACE),
while the remaining 14 events were classified as non-MACE
(Table S2, File S1). Of the six MACE, four occurred in the
IDegLira group (two myocardial infarctions and two cardio-
vascular deaths) and one (myocardial infarction) in each of
the insulin degludec and liraglutide groups. Of the two cardio-
vascular deaths positively adjudicated in the IDegLira group,
one was attributed to sudden death for unknown reasons and
one was a result of cardiopulmonary arrest caused by sepsis.
Out of the 14 non-MACE, 4 occurred in the IDegLira group
[coronary revascularization (4)], 7 occurred in the insulin
degludec group [coronary revascularization (4), unstable
angina pectoris (2), heart failure (1)] and 3 occurred in the
liraglutide group [coronary revascularization (2), unstable
angina pectoris (1)]. Furthermore, two non-treatment cardio-
vascular events were sent for adjudication, one of which was
confirmed as a non-MACE (coronary revascularization) in a
patient previously on liraglutide.
No medullary thyroid carcinomas were reported, and there
were no EAC-confirmed thyroid neoplasms. An increase in
pulse was observed in the IDegLira (mean 1.8 beats/min)
and liraglutide (mean 1.4 beats/min) groups, whereas pulse
remained unchanged with insulin degludec. The ETD regarding
mean change in systolic blood pressure from baseline to week
52 between IDegLira and insulin degludec was −1.54 mmHg
(95% CI −2.89, −0.19; p= 0.0256), while there was no signifi-
cant difference in systolic blood pressure between IDegLira and
liraglutide. Regarding diastolic pressure, there was no signifi-
cant difference between treatment groups from baseline to week
52. An increase from baseline to end of treatment in lipase was
observed in the IDegLira and liraglutide groups (mean 8.3 vs
12.5 units/l, respectively), whereas a decrease was seen in the
insulin degludec group (−7.1 units/l). A lesser absolute mean
increase was observed for amylase with the groups treated with
IDegLira or liraglutide. No clinically relevant changes in other
biochemical or haematological variables, physical examination,
fundoscopy or ECG findings were observed from baseline to
end of treatment in any of the treatment groups.
Discussion
The 52-week data followed the trends of the 26-week results
(shown in Figures 1, 2A, 3; Figures S3 and S5, File S1) from the
DUAL I trial and show sustainability of the glucose-lowering
effect of IDegLira in insulin-naïve patients with T2D previously
inadequately controlled on OADs. No new safety issues were
observed with the longer exposure. The mean HbA1c concen-
tration with IDegLira at 52 weeks [6.4% (47 mmol/mol)] was
significantly lower compared with either insulin degludec [6.9%
(52 mmol/mol)] or liraglutide [7.1% (54 mmol/mol)]. The pre-
specified sensitivity analyses were consistent with these results
(Table S3, File S1). The superior glucose-lowering effects rela-
tive to insulin degludec or liraglutide were observed irrespec-
tive of baseline BMI. A higher percentage of patients receiv-
ing IDegLira achieved HbA1c <7.0% (ADA target) or ≤6.5%
(AACE/IDF target) compared with the percentages for insulin
degludec and liraglutide. This improvement in glucose con-
trol with IDegLira occurred despite the fact that IDegLira
and insulin degludec were titrated to an identical prebreakfast
plasma glucose target.
In contrast to basal insulin degludec insulin used alone,
GLP-1RAs, such as liraglutide, address postprandial glucose
with glucose-dependent stimulation of pancreatic insulin
secretion and glucose-dependent suppression of glucagon
[9,10]. The combined effects of IDegLira on fasting glucose
and of liraglutide on postprandial glucose are the presumed
mechanism for the advantages of IDegLira.
Compared with insulin degludec alone, IDegLira was associ-
ated with a 37% lower mean daily insulin dose at 52 weeks. This
difference in insulin dose was observed for all baseline BMI cat-
egories. Despite the lower insulin dose in the IDegLira group,
the mean FPG was close to the glycaemic target and similar in
both groups. As might be expected with a substantially lower
insulin dose and a weight-decreasing effect from the liraglutide
component, weight gain was avoided with IDegLira, compared
with weight gain with insulin degludec. The presence of the
insulin component in IDegLira was associated with a higher
incidence of hypoglycaemia than liraglutide but a significantly
lower incidence than with insulin degludec, despite the lower
mean HbA1c concentration achieved.
During the 26-week extension of the DUAL I trial, IDegLira
continued to be generally well tolerated without any safety
concerns in relation to the comparators in terms of standard
safety assessments, consistent with the initial 26-week main
phase of the trial. As mentioned in the previous paragraph, over
52 weeks of treatment, the cumulative incidence of confirmed
hypoglycaemia was 37% lower with IDegLira than with insulin
degludec, despite glycaemic control being significantly better
with IDegLira (lower HbA1c). This lower risk of hypoglycaemia
with IDegLira compared with insulin degludec was observed
across all four categories of baseline BMI, and was statistically
significant for the two highest categories.
A greater proportion of patients randomized to liraglutide
withdrew during the 26 weeks of the main phase, compared
with IDegLira or insulin degludec [5] primarily because of
the higher frequency of adverse GI events with liraglutide that
were deemed probably or possibly related to treatment, but a
similar proportion of completers in each group continued in
the extension phase. During the extension trial, GI side effects
were infrequent: all three treatments showed very low rates of
nausea.
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With respect to limitations, this trial was open-label because
the different treatment regimens required different titration
schemes and different injection devices. A double-dummy
design to achieve blinding was regarded as unfeasible because
it would have increased the number of injections to an unac-
ceptable level. The trial assessment was based on objective lab-
oratory values. The analyses of key endpoints by categories of
baseline BMI were not prespecified.
In summary, data from this DUAL I extension trial show
that the glucose-lowering effect of IDegLira was sustained
for a full year without compromising safety and mitigated
the side effects seen with use of the components individually.
Compared with insulin degludec, IDegLira was associated
with a significantly greater reduction in HbA1c concentration,
significantly lower risk of hypoglycaemia, and no (mean)
weight gain over the 52-week treatment period. Compared
with liraglutide, IDegLira was associated with a significantly
greater reduction in HbA1c, significantly greater reduction in
FPG during the entire trial period, and fewer GI adverse events,
especially at treatment initiation. With its effective glycaemic
control and lower incidence of side effects, IDegLira could be
an attractive alternative for insulin-naïve patients to current
treatment intensification options such as initiation of either
basal insulin or GLP-1RAs alone. Because of the lower fre-
quency of GI events compared with GLP-1RAs and the lower
frequency of hypoglycaemia compared with basal insulin, and
because both active ingredients can be co-administered with a
single-daily injection using a simple pen device, IDegLira may
also help overcome clinical inertia with respect to intensifying
therapy [4].
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